The "magic drug" aspirin has added a new effect, or will treat biliary tract cancer!

If there is a magic medicine in the world, it must be aspirin

If there is a magic medicine in the world, it must be aspirin

Aspirin was first discovered and marketed by the German company Bayer in 1898

It is sometimes used as a preventive medicine to prevent strokes and heart attacks , or to try to prevent specific types of cancer .

clevelandclinic

clevelandclinic

In recent years, scientists have discovered that aspirin may have another purpose: to stop cancer cells from spreading in the body in the early stages of tumor formation

In recent years, scientists have discovered that aspirin may have another purpose: to stop cancer cells from spreading in the body in the early stages of tumor formation

So, for biliary tract cancer (BTC), which has an extremely poor treatment effect, can the magic drug show its power again?

Biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer, is the second most common hepatobiliary cancer in the world

Biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer, is the second most common hepatobiliary cancer in the world

About 70% of BTC patients are diagnosed at an advanced stage

To this end, a related study from the Institute of Clinical Medicine, National Yang Ming University, Taiwan, China, aimed to investigate the effect of aspirin use on cancer-specific survival of various BTC subtypes, including gallbladder cancer, ampullary carcinoma of Vater, and bile duct.

To this end, a related study from the Institute of Clinical Medicine, National Yang Ming University, Taiwan, China, aimed to investigate the effect of aspirin use on cancer-specific survival of various BTC subtypes, including gallbladder cancer, ampullary carcinoma of Vater, and bile duct.

We conducted a Taiwan-wide prospective cohort of newly diagnosed BTC between 2007-2015 and followed up until December 31, 2017

The maximum defined daily dose (DDD) of aspirin use was used to assess the dose-response relationship, and the competing risk of cardiovascular death was considered in the analysis

The maximum defined daily dose (DDD) of aspirin use was used to assess the dose-response relationship, and the competing risk of cardiovascular death was considered in the analysis

Post-diagnosis use of aspirin was associated with a 45% lower risk of BTC-specific death compared with non-use of aspirin (HR=0.

For maximum DDD ≤1 and >1, the BTC-specific risk of death was reduced by 47% and 58%, respectively (HR 0.

Further analysis found that among patients with all major BTC subtypes, post-diagnosis use of aspirin was associated with lower cancer-specific mortality
.

Taken together, this study shows that aspirin use after a diagnosis of BTC is associated with improved BTC-specific mortality across subtypes
.
Additional randomized trials are needed in the future to investigate the efficacy of aspirin on BTC
.

Taken together, this study shows that aspirin use after a diagnosis of BTC is associated with improved BTC-specific mortality across subtypes
.
Additional randomized trials are needed in the future to investigate the efficacy of aspirin on BTC
.

references:

references:

Postdiagnosis aspirin use associated with decreased biliary tract cancer–specific mortality in a large nationwide cohort.
 

Postdiagnosis aspirin use associated with decreased biliary tract cancer–specific mortality in a large nationwide cohort.
  Leave a

comment here